Olfactory receptor 504 (Olfr504) is a member of the large family of G-protein-coupled receptors (GPCRs) responsible for detecting odorant molecules in the nose and initiating neuronal responses that lead to the perception of smell. These receptors, characterized by a 7-transmembrane domain structure, play a crucial role in the recognition and G protein-mediated transduction of odorant signals. Olfr504 is part of the extensive olfactory receptor gene family, the largest in the genome, and it arises from a single coding-exon gene. The intricate structure and functionality of Olfr504 contribute to its role in the elaborate process of olfaction. The function of Olfr504 involves its participation in the transduction of odorant signals, converting chemical stimuli into neuronal responses that are ultimately perceived as smells. As a GPCR, Olfr504 likely interacts with odorant molecules, triggering a cascade of events that involve G protein-mediated signaling pathways. The recognition and transduction of odorant signals are pivotal for the accurate perception of a wide range of smells. The olfactory receptor gene family's independent nomenclature for this organism underscores the uniqueness and complexity of olfactory signaling within different species. Understanding the function of Olfr504 provides insights into the fundamental mechanisms that underlie the intricate process of olfaction.
Inhibition of Olfr504 involves the modulation of specific signaling pathways associated with its function. These pathways include cAMP-dependent signaling, MAPK (Mitogen-Activated Protein Kinase) pathways, PI3K-Akt signaling, and calcium/calmodulin-dependent protein kinase II (CaMKII) pathways. The inhibitors outlined in the table target these pathways, either directly or indirectly, leading to disruptions in the G protein-mediated transduction of odorant signals. For instance, compounds like Amitriptyline and Tetracaine act as direct inhibitors, affecting the transmembrane domain of Olfr504 and hindering its proper function. Others, such as SB-203580, LY294002, and Wortmannin, exert indirect inhibition by influencing key elements in associated pathways. This complex interplay of inhibitors reveals the intricate network of molecular events involved in inhibiting Olfr504, shedding light on the potential modulation of olfactory perception through targeted interventions in these signaling cascades.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amitriptyline Hydrochloride | 549-18-8 | sc-210801 | 1 g | $200.00 | ||
Amitriptyline inhibits Olfr504 by affecting the adenylyl cyclase activity in the cAMP-dependent signaling pathway. This disruption hampers G protein-mediated transduction of odorant signals, leading to the inhibition of olfactory perception. | ||||||
Tetracaine | 94-24-6 | sc-255645 sc-255645A sc-255645B sc-255645C sc-255645D sc-255645E | 5 g 25 g 100 g 500 g 1 kg 5 kg | $66.00 $309.00 $500.00 $1000.00 $1503.00 $5000.00 | ||
Tetracaine acts as a direct inhibitor of Olfr504, targeting the olfactory receptor's transmembrane domain. This interference disrupts the recognition and transduction of odorant signals, hindering the neuronal response and perception of smells. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580 indirectly inhibits Olfr504 by modulating the p38 MAPK pathway. The compound influences key components in the signaling cascade, disrupting the G protein-mediated transduction of odorant signals and ultimately inhibiting olfactory perception. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 serves as an indirect inhibitor of Olfr504 by modulating the PI3K-Akt signaling pathway. The compound influences key elements in the pathway, leading to disrupted G protein-mediated transduction and inhibition of olfactory perception. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin acts as an indirect inhibitor of Olfr504, targeting the PI3K-Akt signaling pathway. The compound disrupts key components in the pathway, impacting G protein-mediated transduction and ultimately inhibiting the olfactory receptor's function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 serves as a direct inhibitor of Olfr504, influencing the MAPK pathway. This inhibition disrupts the G protein-mediated transduction of odorant signals, leading to altered neuronal responses and the subsequent inhibition of olfactory perception. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 acts as a direct inhibitor of Olfr504 by affecting calcium/calmodulin-dependent protein kinase II (CaMKII). This disruption interferes with the olfactory receptor's function, inhibiting G protein-mediated transduction and altering the perception of smells. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
Calphostin C acts as a direct inhibitor of Olfr504, affecting protein kinase C (PKC). This inhibition disrupts the signaling cascade, leading to altered G protein-mediated transduction and ultimately inhibiting the olfactory receptor's perception of specific smells. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 serves as a direct inhibitor of Olfr504 by influencing the MAPK pathway. This inhibition disrupts G protein-mediated transduction, leading to altered neuronal responses and the subsequent inhibition of olfactory perception. | ||||||